| Theme | Present Status of Chemoprevention for Tumors Derived from Digestive Diseases | |
|---|---|---|
| Title | Anti-viral Therapy for Prevention of Hepatocellular Carcinogenesis | |
| Publish Date | 2008/11 | |
| Author | Kenji Ikeda | Department of Hepatology, Toranomon Hospital |
| [ Summary ] | The annual carcinogenesis rate for patients with chronic hepatitis type C is approximately 1 to 1. 5 percent of the population. Interferon (IFN) significantly decreases carcinogenesis rates, with hazard ratios of 0.10 in sustained virological response and 0.12 in biochemical response. IFN therapy is less effective in patients with hepatitis C virus-related cirrhosis, in terms of cancer prevention. Hepatocarcinogenesis rates greatly depend on serum HBV DNA concentrations in cases with hepatitis B virus-related cirrhosis. IFN decreases carcinogenesis rates significantly. Cancer-preventive activity is stronger in patients with a high DNA loads at the time of a diagnosis of cirrhosis. Lamivudine treatment for chronic hepatitis B also shows favorable effects in decreasing liver carcinogenesis. |
|